Table 4

Objective response rates by clinical characteristics, HER2 status, and p53 status

Variable	Number of patients[a]	Response rate (%)	P value[b]
Age			0.045
>50 years	108	29	
≤50 years	50	14	
Performance status			0.81
0	77	23	
1 or 2	80	25	
ER			0.056
Positive	70	17	
Negative	71	31	
PR			0.51
Positive	64	22	
Negative	71	27	
ER/PR			0.22
At least 1 positive	81	20	
Both negative	59	29	
Number of metastatic sites			0.50
0–2	139	25	
>2	17	18	
Disease-free interval			0.10
≤2 years	101	20	
>2 years	57	32	
Prior adjuvant chemotherapy			0.83
Yes	94	24	
No	61	23	
HER2 CBll			0.96
Positive	30	23	
Negative	126	24	
HER2 FISH			0.70
Positive	37	22	
Negative	109	25	
HER2 HercepTest			0.026
Positive: 2–3	46	35	
Negative: 0–1	105	18	
HER2 HercepTest			0.98
Positive: 3	30	23	
Negative: 0–2	121	23	
p53 IHC			0.79
Positive	56	23	
Negative	89	21	
p53 Mutation			0.55
Present	42	21	
Absent	103	26	

[a]Not all patients could be evaluated for a response, and those who could not be evaluated have been excluded. [b]P values are for comparisons of the proportion of patients with a response to paclitaxel in each group. ER, estrogen receptor; FISH, fluorescent *in situ* hybridization; IHC, immunohistochemistry; PR, progesterone receptor.